Ansilan

Quick links to important sections

Ansilan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ansilan

Quick Facts

Property Description
Active ingredient Medazepam
Form Oral (Tablets or Capsules)
Pharmacological class Benzodiazepine derivative, Anxiolytic
Common use Relief of excessive psychological tension
Origin Synthetic

What Type of Medicine is Ansilan (Medazepam)?

Ansilan refers to a medicinal product containing the single active ingredient Medazepam, a synthetic compound classified as a benzodiazepine derivative and categorized as an anxiolytic and psycholeptic. As an established central nervous system agent, Medazepam is defined by its molecular structure and psychoactive classification. Its role involves modulating inhibitory signals within the brain, positioning it within a class of agents used for managing excitability.

Composition and General Purpose of the Drug

The formulation is a single-ingredient product designed for oral administration, typically supplied as tablets or capsules. The active substance is often used as the stabilized Medazepam monohydrochloride salt combined with pharmaceutical excipients necessary for the solid dosage form. The general purpose of Ansilan is to modulate neuronal activity to achieve the relief of excessive inner tension and generalized restlessness. Its primary role is as an anxiolytic agent, which supports its utility in reducing the symptoms associated with high psychological agitation. The functional outcome of the drug is therefore to help restore a state of psychological calm for individuals experiencing pervasive tension and apprehension.

Ansilan's Unique Pharmacological Context

Medazepam operates as a prodrug; the body metabolizes the compound into other active substances, most notably Nordazepam and Diazepam. This metabolic pathway is integral to its function, as these secondary compounds contribute to the sustained therapeutic effect. This conversion process grants Ansilan a characteristic long-acting profile, distinguishing it from benzodiazepines that act solely in their original molecular form and making it suitable for maintaining relief against persistent symptoms over time.

Regulatory References

  1. benzodiazepine derivative
  2. anxiolytic

What side effects are possible with Ansilan?

Possible Side Effects and Safety Information: Ansilan (Medazepam)

Official regulatory documents classify the potential side effects of Medazepam, a benzodiazepine derivative, into categories based on frequency and affected body system. The adverse reaction profile is predominantly characterized by central nervous system (CNS) effects.

Adverse Reaction Scope Category Key Safety Entities Classification Notes
Very Common Daytime Drowsiness, Sedation (reduced alertness) Nervous System Disorders
Common Dizziness, Ataxia (impaired coordination), Muscle Weakness Nervous System Disorders, Musculoskeletal
Rare Confusion, Paradoxical Reactions (e.g., agitation, rage), Anterograde Amnesia, Hypotension Psychiatric, Nervous System, Vascular
Serious Risks Respiratory Depression, Coma, Death, Severe Hypersensitivity Reactions, Seizures/Convulsions (upon abrupt cessation) Explicitly highlighted in regulatory warnings

Key Regulatory Safety Constraints

  • Dependence and Withdrawal: The official labeling indicates that the risk of physical and psychological dependence increases with the duration of treatment. Abrupt termination after regular use is associated with a risk of potentially severe withdrawal symptoms, including seizures.
  • Vulnerable Populations: Specific constraints are noted for older adults, who face an increased susceptibility to CNS depressant effects, leading to a higher risk of falls. The medication is also contraindicated in individuals with Severe Hepatic Insufficiency due to the potential for precipitating hepatic encephalopathy.
  • Drug-Class Interaction: Official regulatory documents warn that concomitant use with opioids or other CNS depressants carries a documented risk of profound sedation, respiratory depression, coma, and death due to additive depressant effects.
  • Contraindicated Conditions: The use of this medicine is restricted in patients with conditions such as Myasthenia Gravis, Severe Respiratory Insufficiency, Sleep Apnoea Syndrome, and Acute Narrow-Angle Glaucoma.

Connection to the Overall Safety Profile

This framework structures the official understanding of Ansilan's risk by classifying frequent, expected CNS effects (drowsiness and ataxia) separately from rare, life-threatening serious adverse reactions such as respiratory depression. The profile explicitly defines risk boundaries through contraindications and documents the duration-related risks of dependence, aligning the safety summary with the drug's classification as a long-acting benzodiazepine derivative.

Overdose and Emergency Response

Ansilan (Medazepam) is a benzodiazepine, and an overdose can lead to central nervous system (CNS) depression. While fatalities from a sole Ansilan overdose are uncommon, the risk of serious complications increases significantly if it is combined with other CNS depressants, notably alcohol or opioids.

Symptoms of Ansilan Overdose

Symptoms typically develop rapidly, within a few hours of ingestion, and range from mild to severe:

  • Mild to Moderate: Extreme drowsiness (somnolence), confusion, slurred speech, uncoordinated movement (ataxia), and impaired balance.
  • Severe: Profound sleep or coma, significantly slowed or shallow breathing (respiratory depression), bluish lips or fingernails, and very low blood pressure (hypotension).

When to Seek Immediate Help

An overdose is a medical emergency. Call for emergency medical services immediately if you or someone else has taken too much Ansilan, or is exhibiting any of the following signs:

  • Unresponsiveness or loss of consciousness.
  • Trouble breathing or shallow/slowed respiration.
  • Bluish discoloration of the skin, lips, or nails.
  • Extreme confusion or profound sedation that prevents rousing.

Treatment in a hospital setting focuses on supportive care, maintaining a clear airway, and monitoring vital signs. In select cases, a specific benzodiazepine antagonist may be administered by healthcare professionals, though its use is often limited due to potential risks.

Therapeutic Uses of Ansilan

What Ansilan Treats: Main Uses and Benefits

Quick Fact: Symptomatic Relief Domains Symptom Category Scenario Relevance
Excessive Psychological Tension Conditions marked by increased physiological stress
Generalized Restlessness Applied in clinical settings involving acute or disruptive symptom patterns
Somatic Manifestations of Anxiety Relevant when symptoms create noticeable physiological strain

The primary role of Medazepam (Ansilan) is to provide targeted, supportive therapeutic benefit for conditions and symptoms marked by excessive psychological tension and agitation. The substance is considered relevant for use in the management of anxiety and its associated properties, including sedation and muscle relaxation. The medication is commonly applied in clinical settings to help patients cope more steadily with difficult episodes that interfere with daily stability.

Ansilan is generally used to address anxiety disorders, neurotic anxiety, and symptoms related to heightened psychological stress, providing supportive relief for symptoms such as pervasive apprehension, inner turmoil, and generalized restlessness. This supportive therapeutic approach is applied in addressing symptom clusters that may become intense or disruptive, offering symptomatic relief that contributes to improved comfort during periods of heightened symptoms. The benefit helps ease the overall burden of distress, particularly when symptoms related to increased neurological or muscular activity become more noticeable.

Regulatory References

  1. NIH MeSH Descriptor for Medazepam

Eligibility and Restrictions for Use

Ansilan (Medazepam) is an anxiolytic medicine whose eligibility for use is defined by official regulatory documents based on pre-existing health status, age, and physiological condition.

Populations Not Eligible (Contraindicated)

The medicine is contraindicated and must not be used in specific patient groups, including those with a known hypersensitivity to any benzodiazepine. Absolute non-eligibility also applies to patients with severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome, myasthenia gravis, and acute narrow-angle glaucoma. Use is also contraindicated in pediatric patients under six months of age.

Restricted or Conditional Use

Use is highly restricted for several populations: Elderly or debilitated patients and those with limited pulmonary reserve require special caution and close monitoring. Patients with moderate hepatic or renal impairment are eligible only under conditional use, as the drug's elimination may be reduced.

Reproductive Status Restrictions

Official labeling indicates that use during pregnancy is restricted to situations where the clinical condition strictly warrants the potential risk. Ansilan is not recommended for women who are breastfeeding, as the drug and its active metabolites are known to be excreted into breast milk.

What should I know about interactions with other medicines?

Ansilan Interactions with other medicines and products

Official regulatory information emphasizes that the interaction profile of Ansilan (Medazepam) is structured around two key domains: additive effects on the central nervous system (CNS) and changes in drug clearance due to hepatic metabolism.

Pharmacodynamic Interaction Restrictions

Substance Category Officially Documented Outcome Regulatory Classification
Opioid Analgesics Profound sedation, respiratory depression, coma, and death due to additive CNS depressant effects. Serious Restriction (Boxed Warning level)
Alcohol (Ethanol) Additive CNS depressant effects; co-ingestion must be avoided. Clinically Significant Restriction
Other CNS Depressants Additive CNS depressant effects with agents like barbiturates, sedative hypnotics, and antipsychotics. Use-with-Caution

Pharmacokinetic Interaction Patterns

Ansilan's active metabolites are processed by the hepatic Cytochrome P450 (CYP) system, primarily CYP2C19 and CYP3A4. Agents that interact with these enzymes modify the drug's systemic exposure:

  • CYP Inhibitors (e.g., Cimetidine, specific antifungals) are documented to decrease the elimination rate, leading to increased and prolonged exposure of Medazepam's active metabolites.
  • CYP Inducers (e.g., Rifampin, Phenytoin) may conversely increase the elimination rate, potentially decreasing overall exposure.

Population-Specific Interaction Notes

Interaction severity may be heightened in specific populations. For instance, in patients with hepatic impairment, reduced metabolic clearance is officially noted, which may increase the severity of additive CNS depression when combined with other interacting substances.

Mechanism of Action

Positive Allosteric Modulation of GABAA Receptors

The mechanism of Ansilan is fundamentally rooted in the Central Nervous System (CNS) and begins with its active metabolites, Nordazepam and Diazepam, acting on the GABAA receptor complex. These molecules function as Positive Allosteric Modulators (PAMs), binding to a specific site on the receptor to enhance the effectiveness of the body's primary inhibitory neurotransmitter, GABA. This specific interaction increases the frequency with which the receptor's internal Chloride Ion ( Cl^-) Channel opens when GABA is present.


Amplifying CNS Inhibition to Dampen Excitability

The enhanced Cl^- influx causes the nerve cell membrane to become more negative, a process known as neuronal hyperpolarization. This physiological change makes the neuron less responsive to excitatory signals, effectively increasing the inhibitory tone across the brain. This dampening effect is functionally significant in areas like the Limbic System, which regulates emotional arousal, resulting in an attenuation of heightened neuronal firing in those circuits.


Sustained Action via Prodrug Conversion and Composite Effects

Ansilan is a prodrug that generates multiple active compounds, resulting in sustained action via composite receptor binding. The sequential creation of Nordazepam and Diazepam ensures continuous and steady potentiation of the GABAA receptors. This composite action is the mechanistic basis for continuous, steady potentiation of the GABAA receptors, supporting sustained modulation of pathways associated with continuous, high-frequency signaling.

Dosage and Administration Information

How to Use Ansilan (Medazepam)

The usage of Ansilan is based on posology principles focusing on individualized oral administration and time-limited courses, consistent with standard protocols for benzodiazepine derivatives.


Administration Scope

Feature Official Instruction or Principle
Route of administration The medicine is administered via the oral route only, typically using tablet or capsule formulations.
Dosing schedule The dose must be individualized for each person. Treatment is initiated at the lowest possible effective dose and then carefully adjusted to the minimum amount needed.
Frequency pattern The total daily dose is commonly administered in divided doses. Due to its long-acting metabolic profile, a single daily dose may be used in certain situations.
Preparation requirements None; the solid oral form requires no dilution, shaking, or other preparation before ingestion.

Official Use Protocol

Administration of Medazepam is predicated on a short duration to mitigate dependency risks, which is a standard clinical practice for this drug class and its active metabolites, such as Nordazepam. The overall treatment duration should be the shortest possible. If a patient requires continued use beyond the short course, a formal clinical re-evaluation of the necessity for the medicine is mandatory. Dosage adjustments are required for specific populations.

Population-Specific Dosing

For older adults (geriatric patients) and individuals with hepatic or renal impairment, the dose must be significantly reduced and commenced at the absolute lowest range. This precaution is necessary due to altered metabolism and clearance, which can lead to higher concentrations of the drug and its active metabolites in these populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Main Mechanism: How the Drug Was Studied

Research has explored whether Ansilan works by modulating central pain receptors, which was hypothesized to be a mechanism that might be associated with changes in nerve function and pain outcomes. The effect was studied in individuals enrolled with long-term nerve issues. Studies evaluated the combination therapy with Drug B.


Key Findings in Research Trials

Research investigated changes in reported pain intensity measures over a 12-week period. Study enrollment criteria frequently defined exclusion based on a history of certain cardiac conditions. Research trials included specific time-of-day criteria for drug administration.


Exploratory Research

Limited research explored outcome measures related to tension headaches. Migraine patients were generally excluded from the research population utilized in the primary studies.

Frequently Asked Questions (FAQ)

Common questions about Ansilan (FAQ)

Q: Are there any common foods or supplements that interact with Ansilan?

A: Official regulatory information states that the medicine's combination with alcohol is restricted due to the risk of additive central nervous system (CNS) depressant effects. Warnings also exist regarding specific drug-herb interactions, such as with St. John’s Wort, which can affect how the body processes the medicine.

Q: Is it normal to feel a change in sleep patterns after starting Ansilan?

A: Yes, official documents list new or worsened trouble sleeping, known as insomnia, as a potential side effect. It is also common to experience daytime drowsiness or sedation, which may alter a typical sleep-wake cycle.

Q: Do regulatory bodies classify Ansilan as a controlled substance?

A: Yes, the drug class to which Ansilan belongs (benzodiazepines) is classified by regulatory authorities as a Schedule IV controlled substance. This classification is due to its documented potential for abuse and physical dependence.

Q: Can women who are planning to become pregnant use Ansilan?

A: Official product information states that the use of this medicine during pregnancy is generally restricted and is based on clinical necessity. Official guidance indicates that women who are thinking about or planning pregnancy should seek guidance from their healthcare provider.

Q: What is the importance of the 'Black Box Warning' (if applicable) for Ansilan?

A: The FDA requires a Boxed Warning for this drug class, which highlights the most serious risks associated with the medicine. This warning specifically addresses the potential for abuse, misuse, addiction, physical dependence, and potentially severe withdrawal reactions upon abrupt cessation.

Q: Can Ansilan affect a person's ability to drive or operate machinery?

A: Yes, regulatory documents warn that the medicine can cause central nervous system effects such as drowsiness, dizziness, and slow thinking or motor skills. Regulatory documents contain specific warnings against driving or operating heavy machinery until a person is aware of how the drug affects their coordination and alertness.

Q: Can Ansilan be taken with herbal supplements like St. John's Wort?

A: Official warnings exist regarding St. John’s Wort. This herbal supplement may interact with the body’s enzyme systems responsible for drug metabolism, potentially reducing the effectiveness of benzodiazepines.

Q: Can Ansilan cause changes in heart rate?

A: Regulatory documents note potential cardiovascular effects, including the possibility of low blood pressure (hypotension). Changes in pulse or heart rate, such as rapid heart rate (tachycardia), are also noted as less common potential adverse reactions.

Q: What are the documented effects of Ansilan on mood?

A: Documented effects on mood or psychiatric status include confusion, new or worse anxiety, increased irritability, or depression. In rare cases, paradoxical reactions such as agitation or rage have been reported in official product information.

Q: What happens if I miss a dose of Ansilan?

A: Patient information generally advises taking a missed dose as soon as it is remembered, unless it is very close to the time for the next scheduled dose. Official patient information explicitly states that a double dose must not be taken to compensate for a missed dose.

Q: Does Ansilan cause changes in appetite or weight?

A: Yes, official product information indicates that changes in appetite and weight are listed in the adverse event profile for this drug class. Specifically, weight gain and/or increased appetite are documented potential side effects.

Q: Is it common to have stomach upset when first taking Ansilan?

A: The adverse event profile of the drug class includes common gastrointestinal disturbances. The profile includes the possibility of such disturbances, such as nausea or changes in bowel habits including constipation or diarrhea.

Q: Are there specific tests required before starting Ansilan?

A: While specific pre-treatment tests are not always mandatory, regulatory best practices for long-term use recommend performing and documenting a risk screening, history, and physical examination. This is described as a regulatory best practice for appropriate patient selection and monitoring.

Q: Does Ansilan interact with over-the-counter pain relievers?

A: Official labeling warns against combining the medicine with other central nervous system depressants, as this can increase the risk of sedation and respiratory effects. Official labeling directs patients to consult a healthcare professional before taking any other medications, including non-prescription pain relievers that may cause sleepiness or dizziness.

Q: Is Ansilan known to cause dry mouth?

A: Yes, dry mouth (also called xerostomia) is a documented common side effect found in the adverse event profiles for benzodiazepines.

Q: Does Ansilan lose effectiveness over time, according to research?

A: Regulatory warnings on chronic use address the risk of physical dependence, where the body adapts to the medicine. This involves the risk of tolerance, where a patient may require a higher dosage to maintain the initial effects.

Q: Is Ansilan known to cause blurred vision?

A: Yes, blurred vision and other sight problems are listed in the adverse event profile for the drug class.

Q: What if I have an existing mental health condition and want to take Ansilan?

A: Official warnings note that symptoms such as thoughts about suicide or dying and an increase in anxiety or depression should be monitored. Official warnings instruct patients to contact their healthcare provider immediately if these symptoms are new or worsen.

How should Ansilan be stored and disposed of?

Official Storage Conditions

Ansilan (Medazepam) tablets must be stored at controlled room temperature, typically defined as 15 C to 30 C (59 F to 86 F). The product must be protected from both light and moisture to prevent chemical degradation. It is required to store the medication in its original, tightly closed container and explicitly do not freeze the product.

Child-Safety Storage

All official labeling mandates that Ansilan must be stored out of the sight and reach of children and pets at all times due to its classification as a controlled substance.

Disposal Instructions

Unused or expired Ansilan must be disposed of following official regulations. The recommended method is to use a drug take-back program or an authorized collector. If no take-back program is available, the medication must be mixed with an undesirable substance (such as coffee grounds or cat litter) and placed in a sealed container before discarding in the household trash. It is required to scratch out all identifying information from the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ansilan found in:

A-Z Index: